BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Research

QingSong Health and Basel Medical Group Forge Strategic Alliance to Advance AI Healthcare in Southeast Asia

QingSong Health Corp (2661.HK) and Basel Medical Group Ltd announced the signing of a Memorandum of Strategic Cooperation. The two parties i...

June 15, 2026 | News

Elixiron Advances Precision Immunotherapy Strategy with Encouraging Alzheimer's Data

Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmun...

June 15, 2026 | News

Rejuvenate Bio and Merck Animal Health Join Forces on Novel Animal Health Gene Therapy Programme

-- Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human healthspan, congratulates its portfolio company Rejuvenate...

June 15, 2026 | News

Akeso Expands Immunology Franchise with Approval of Gumokimab for Psoriasis

Akeso, Inc. announced that the National Medical Products Administration (NMPA) of China has approved gumokimab (AK111), the company's internally-devel...

June 15, 2026 | News

Formation Bio Doses First Participant in Phase I Trial of Lynk’s CNS-Penetrant TYK2 Inhibitor

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on autoimmune and inflammatory diseas...

June 12, 2026 | News

Harbour BioMed Secures China IND Acceptance for Novel Bispecific Cancer Therapy HBM7004

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...

June 12, 2026 | News

China Clears Adcentrx’s ADRX 0405 For Clinical Development In Advanced Solid Tumours

Follows initiation of Phase 1a/1b study in the U.S. Adcentrx intends to include clinical centers in China to broaden geographic repr...

June 10, 2026 | News

Mabwell's First In Class Autoimmune Antibody 9MW5211 Wins China Clinical Trial Approval for IBD

Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently...

June 08, 2026 | News

Travere Secures Global Rights to Civorebrutinib in $1.14 Billion Kidney Disease Partnership with Everest Medicines

Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immun...

June 04, 2026 | News

Lynk Pharmaceuticals Advances LNK01004 Into Phase II Trials For Vitiligo And Chronic Hand Eczema

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...

June 02, 2026 | News

ImmVira Reports 100% Complete Response Rate With MVR T3011 In BCG Unresponsive Bladder Cancer

ImmVira Group announced that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy candidate, was presented at the 2026 Ameri...

June 02, 2026 | News

Leica Biosystems Expands AstraZeneca And Daiichi Sankyo Collaboration To Advance AI Driven Lung Cancer Biomarker Research

Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions,announced an expansion of its strategic coll...

June 01, 2026 | News

Antengene Receives CDE Endorsement For Pivotal Phase III Study Of CLDN18.2 ADC In Gastric Cancer

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, d...

May 29, 2026 | News

Ribo Submits Phase 2 CTA To EMA For siRNA Therapy Targeting Coronary Artery Disease

Suzhou Ribo Life Science (stock code 06938.HK) and Ribocure Pharmaceuticals (together "Ribo") announce the submission of Phase 2 Clinical Trial Application...

May 29, 2026 | News

Stay Connected